ReviewWorld journal of gastroenterology2022
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- Platelet-to-high-density lipoprotein ratio predicts postoperative overall survival in hepatocellular carcinoma: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Article
- Enhancement of Platinum-based Drug Sensitivity in Ovarian Cancer Cells Through Hyperthermia-induced Activation of the TGF-β1/β-Catenin Signaling Pathway.Current molecular medicine · 2026Article
- New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Review
- Article
- Lifestyle factors in hepatocellular carcinoma: From pathogenesis to prognosis.World journal of clinical oncology · 2025Review
- Editorial: Immunomodulatory molecules of natural origin: innovative strategies for combatting cancer.Frontiers in oncology · 2025Article
- Transforming growth factor-β (TGF-β) signaling pathway-related genes in predicting the prognosis of colon cancer and guiding immunotherapy.Cancer pathogenesis and therapy · 2024Article
- Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.Biomedicines · 2024Review
- Article
- Physical activity and exercise in liver cancer.Liver research (Beijing, China) · 2024Review
- Effect of curcumin nanoparticles on proliferation and migration of mouse airway smooth muscle cells and airway inflammatory infiltration.Frontiers in pharmacology · 2024Article
- Different origin-derived exosomes and their clinical advantages in cancer therapy.Frontiers in immunology · 2024Review
- New and Old Key Players in Liver Cancer.International journal of molecular sciences · 2023Review
- Cellular senescence-related genes: predicting prognosis in hepatocellular carcinoma.BMC cancer · 2023Article
- Kaempferide exhibits an anticancer effect against hepatocellular carcinoma in vitro and in vivo.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Review
- Research progress of exosomes in drug resistance of breast cancer.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional cytokine that performs a dual role as a tumor suppressor and tumor promoter during cancer progression. Among different ligands of the TGF-β family, TGF-β1 modulates most of its biological outcomes. Despite the abundant expression of TGF-β1 in the liver, steatosis to hepatocellular carcinoma (HCC) progression triggers elevated TGF-β1 levels, contributing to poor prognosis and survival. Additionally, elevated TGF-β1 levels in the tumor microenvironment create an immunosuppressive stage
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.